{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:46:53Z","timestamp":1788536813694,"version":"build-2803163510"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1097\/adm.0b013e3181d41ddb","type":"journal-article","created":{"date-parts":[[2010,5,26]],"date-time":"2010-05-26T05:31:19Z","timestamp":1274851879000},"page":"21-27","source":"Crossref","is-referenced-by-count":149,"title":["Adoption and Implementation of Medications in Addiction Treatment Programs"],"prefix":"10.1097","volume":"5","author":[{"given":"Hannah K.","family":"Knudsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210126","doi-asserted-by":"crossref","first-page":"628","DOI":"10.15288\/jsad.2009.70.628","article-title":"Counselor attitudes toward pharmacotherapies for alcohol dependence.","volume":"70","author":"Abraham","year":"2009","journal-title":"J Stud Alcohol Drugs"},{"key":"R2-4-20210126","article-title":"Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction (Treatment Improvement Protocol Series 40, DHHS Publication SMA 04-3939).","year":"2004"},{"key":"R3-4-20210126","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1747-597X-3-17","article-title":"State policy influence on the early diffusion of buprenorphine in community treatment programs.","volume":"3","author":"Ducharme","year":"2008","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"suppl 1","key":"R4-4-20210126","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/01.jcp.0000246209.18777.14","article-title":"Trends in the adoption of medications for alcohol dependence.","volume":"26","author":"Ducharme","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R5-4-20210126","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jsat.2006.05.021","article-title":"Innovation adoption in substance abuse treatment: Exposure, trialability, and the clinical trials network.","volume":"32","author":"Ducharme","year":"2007","journal-title":"J Subst Abuse Treat"},{"key":"R6-4-20210126","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1037\/a0013420","article-title":"Understanding attitudes toward use of medications in substance abuse treatment: A multilevel approach.","volume":"6","author":"Fitzgerald","year":"2009","journal-title":"Psychol Serv"},{"key":"R7-4-20210126","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11414-009-9169-z","article-title":"Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs.","volume":"373","author":"Friedmann","year":"2010","journal-title":"J Behav Health Serv Res"},{"key":"R8-4-20210126","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jsat.2005.02.003","article-title":"Adoption of naltrexone to treat alcohol dependence.","volume":"28","author":"Fuller","year":"2005","journal-title":"J Subst Abuse Treat"},{"key":"R9-4-20210126","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1475-6773.2007.00812.x","article-title":"Role of state policies in the adoption of naltrexone for substance abuse treatment.","volume":"43","author":"Heinrich","year":"2008","journal-title":"Health Serv Res"},{"key":"R10-4-20210126","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jsat.2007.02.004","article-title":"Availability of medications in private health plans.","volume":"34","author":"Horgan","year":"2008","journal-title":"J Subst Abuse Treat"},{"key":"R11-4-20210126","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1300\/J069v25n04_09","article-title":"Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence.","volume":"25","author":"Kissin","year":"2006","journal-title":"J Addict Dis"},{"key":"R12-4-20210126","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jsat.2008.12.004","article-title":"Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.","volume":"37","author":"Knudsen","year":"2009","journal-title":"J Subst Abuse Treat"},{"key":"R13-4-20210126","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jsat.2006.03.013","article-title":"Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors.","volume":"30","author":"Knudsen","year":"2006","journal-title":"J Subst Abuse Treat"},{"key":"R14-4-20210126","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drugalcdep.2006.08.013","article-title":"The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters.","volume":"87","author":"Knudsen","year":"2007a","journal-title":"Drug Alcohol Depend"},{"key":"R15-4-20210126","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/002214650704800207","article-title":"The use of antidepressant medications in substance abuse treatment: The public-private distinction, organizational compatibility, and the environment.","volume":"48","author":"Knudsen","year":"2007b","journal-title":"J Health Soc Behav"},{"key":"R16-4-20210126","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1176\/ps.2007.58.1.55","article-title":"Racial and ethnic disparities in SSRI availability in substance abuse treatment.","volume":"58","author":"Knudsen","year":"2007c","journal-title":"Psychiatr Serv"},{"key":"R17-4-20210126","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsat.2005.05.002","article-title":"Buprenorphine diffusion: The attitudes of substance abuse treatment counselors.","volume":"29","author":"Knudsen","year":"2005a","journal-title":"J Subst Abuse Treat"},{"key":"R18-4-20210126","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0740-5472(03)00158-2","article-title":"Modeling the use of innovations in private treatment organizations: The role of absorptive capacity.","volume":"26","author":"Knudsen","year":"2004","journal-title":"J Subst Abuse Treat"},{"key":"R19-4-20210126","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/002204260503500308","article-title":"Organizational predictors of pharmacological innovation adoption: The case of disulfiram.","volume":"35","author":"Knudsen","year":"2005b","journal-title":"J Drug Issues"},{"key":"R20-4-20210126","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.drugalcdep.2005.12.005","article-title":"Characteristics of US substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.","volume":"83","author":"Koch","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"R21-4-20210126","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0376-8716(03)00134-0","article-title":"Understanding US addiction physicians' low rate of naltrexone prescription.","volume":"71","author":"Mark","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"R22-4-20210126","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1046\/j.1524-4733.2003.64247.x","article-title":"Using stated preference modeling to forecast the effect of medication attributes on prescriptions of alcoholism medications.","volume":"6","author":"Mark","year":"2003","journal-title":"Value Health"},{"key":"R23-4-20210126","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/hec.845","article-title":"Using stated preference and revealed preference modeling to evaluated prescribing decisions.","volume":"13","author":"Mark","year":"2004","journal-title":"Health Econ"},{"key":"R24-4-20210126","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jsat.2008.06.006","article-title":"Factors affecting willingness to provide buprenorphine treatment.","volume":"36","author":"Netherland","year":"2009","journal-title":"J Subst Abuse Treat"},{"key":"R25-4-20210126","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/ADM.0b013e31814c3fa8","article-title":"Factors determining how early adopter physicians use buprenorphine in treatment.","volume":"1","author":"Reif","year":"2007","journal-title":"J Addict Med"},{"key":"R26-4-20210126","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jsat.2006.09.002","article-title":"Client and counselor attitudes toward the use of medications for treatment of opioid dependence.","volume":"32","author":"Rieckmann","year":"2007","journal-title":"J Subst Abuse Treat"},{"key":"R27-4-20210126","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0740-5472(02)00241-6","article-title":"Adoption and implementation of new technologies in substance abuse treatment.","volume":"22","author":"Roman","year":"2002","journal-title":"J Subst Abuse Treat"},{"key":"R28-4-20210126","article-title":"National Survey of Substance Abuse Treatment Services: 2007.","year":"2008"},{"key":"R29-4-20210126","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1176\/ps.2008.59.8.909","article-title":"Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists.","volume":"59","author":"Thomas","year":"2008","journal-title":"Psychiatr Serv"},{"key":"R30-4-20210126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0740-5472(02)00319-7","article-title":"Research to practice: Adoption of naltrexone in alcoholism treatment.","volume":"24","author":"Thomas","year":"2003","journal-title":"J Subst Abuse Treat"},{"key":"R31-4-20210126","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2005.06.010","article-title":"Medications development: Successes and challenges.","volume":"108","author":"Vocci","year":"2005","journal-title":"Pharmacol Ther"},{"key":"R32-4-20210126","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11414-008-9132-4","article-title":"Substance abuse treatment organizations as mediators of social policy: Slowing the adoption of a congressionally approved medication.","volume":"37","author":"Wallack","year":"2010","journal-title":"J Behav Health Serv Res"}],"container-title":["Journal of Addiction Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ADM.0b013e3181d41ddb","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:20:20Z","timestamp":1786040420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01271255-201103000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/adm.0b013e3181d41ddb","relation":{},"ISSN":["1932-0620"],"issn-type":[{"value":"1932-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}